TORII PHARMACEUT.

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2025, TORII PHARMACEUT. has already paid €0.37 in dividends. The last payout was in March 2025.

Financials

In the last quarter, TORII PHARMACEUT. had revenue of €98.5m and net profit of €7.06m

(EUR)	June 2025	YoY
Revenue	98.5m	-
Gross profit	42.13m	-
Net profit	7.06m	-
EBITDA	9.63m	-

Fundamentals

Metric	Value
Market capitalization	€1.02bn
Number of shares	28.12m
52-week high/low	€69,561,127.84 - €20.15
Dividends	No
Beta	0.12
P/E ratio	35.40
PEG ratio	12.08
P/B ratio	1.47
P/S ratio	2.95

Company profile

Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents, such as Riona for the treatment of hyperphosphatemia; and REMITCH, an oral therapeutic agent used for the treatment of pruritus in dialysis and liver disease patients. The company also provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; allergen immunotherapy tablets comprising CEDARCURE and MITICURE; and CEDARTOLEN, a sublingual immunotherapy drug. Torii Pharmaceutical Co., Ltd. markets its products primarily through medical representatives for medical professionals. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc.